Responsiveness of lower airways in adult patients (18-60 Years) with stable asthma after treatment with ciclesonide and fluticasone propionate (BY9010/NL-101)
Study identifier:BY9010/NL-101
ClinicalTrials.gov identifier:NCT00306163
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
Nebulizer Trial: Evaluation of the influence of particle size of aerosolized AMP on bronchial responsiveness in patients with asthma and the effects of treatment with ciclesonide versus fluticasone.
Medical condition
asthma
Phase
Phase 3
Healthy volunteers
No
Study drug
Ciclesonide, Fluticasone
Sex
All
Actual Enrollment
37
Study type
Interventional
Age
18 Years - 60 Years
Date
Study Start Date: 01 May 2006
Primary Completion Date: 01 Aug 2008
Study Completion Date: 01 Sept 2008
Study design
Allocation: Randomized
Endpoint Classification: None
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment
Verification:
Verified 01 Sept 2016 by AstraZeneca
Sponsors
AstraZeneca
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| Active Comparator: 1 Ciclesonide 160 µg | Drug: Ciclesonide inhaled Ciclesonide 160 µg, once daily in the morning |
| Active Comparator: 2 Fluticasone 100 µg | Drug: Fluticasone inhaled Fluticasone 100 µg, twice daily |
Contacts
Investigators
Principal Investigator
AstraZeneca AstraZeneca
AstraZeneca
